Selective Inhibition of Histone Deacetylases Sensitizes Malignant Cells to Death Receptor Ligands

Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-09-0495
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Innovative Strategies for Selective Inhibition of Histone Deacetylases

Cell Chemical Biology
Molecular MedicineMolecular BiologyPharmacologyBiochemistryClinical BiochemistryDrug Discovery
2016English

Phosphatidylinositol 3-Kinase Inhibition Broadly Sensitizes Glioblastoma Cells to Death Receptor- And Drug-Induced Apoptosis

Cancer Research
Cancer ResearchOncology
2008English

Rapamycin Sensitizes Akt Inhibition in Malignant Human Breast Epithelial Cells

Cancer Letters
Cancer ResearchOncology
2010English

Brca2Deficiency Sensitizes Cells to PARP Inhibition

Cancer Research
Cancer ResearchOncology
2006English

Inhibition of Histone Deacetylases in Cancer Therapy: Lessons From Leukaemia

British Journal of Cancer
Cancer ResearchOncology
2016English

Triptolide Sensitizes Pancreatic Cancer Cells to TRAIL-induced Activation of the Death Receptor Pathway

Cancer Letters
Cancer ResearchOncology
2014English

The Antidiabetic Agent LG100754 Sensitizes Cells to Low Concentrations of Peroxisome Proliferator-Activated Receptor Γ Ligands

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
2002English

Adenosine Mimetics as Inhibitors of NAD+-Dependent Histone Deacetylases, From Kinase to Sirtuin Inhibition

English

Targeting HSF1 Sensitizes Cancer Cells to HSP90 Inhibition

Oncotarget
Oncology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy